Tedalinab

Tedalinab

Systematic (IUPAC) name
(4S,7R)-1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-4,7-methano-1H-indazole-3-carboxamide
Identifiers
CAS Number	916591-01-0
PubChem	CID: 24872953
Chemical data
Formula	C19H21F2N3O
Molecular mass	345.385 g/mol
SMILES CC(C)(C)NC(=O)C1=NN(C2=C1[C@@H]3CC[C@H]2C3)C4=C(C=C(C=C4)F)F

Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB₂ receptor agonist. It has a very high selectivity of 4700x for CB₂ over the related CB₁ receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials. A large number of related compounds are known, most of which also show high CB₂ selectivity.

See also

• CBS-0550
• SER-601